Clinical Trial Search

Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells

Primary: Survival Rate of the Rejuvenate Modular Stem/Neck — 8 Surviving Hips

Primary: Independent Photo Reviewer Fitzpatrick Wrinkle and Elastosis Scale (FWS) — 55 Participants — p=<.0001

Primary: Average Percent Hemoglobin (HbA) Decrement Per Day — 0.629; 0.659 %HbA per day — p=0.95

Primary: C-GAIS by the PI or Designee — 1.22; 2.13; 1.75; 2.75 units on a scale

Primary: Number of Genes Upregulated or Downregulated as Assessed by RNA Sequencing (Older Group, Retinol Versus Placebo) — 23; 21 genes

Primary: The Primary Objective of This Study is to Determine the Efficacy and Longevity of the Use of Restylane® and Perlane® in Combination for the Rejuvenation of the…

Primary: Change From Baseline in Texture Score at Visit 4 (End-of-study Session) — 0.25; -4.75 score on a scale — p=0.075

Primary: Nasal Tip Projection — 0.601 ratio

Primary: Changes in Facial Scarring Score — -.50 score on a scale

Primary: Change From Baseline in Mitochondrial Respiration in Muscle — -3.05; -4.82; -4.56 nmol O2/s/mg wwt

Primary: Skin Aging Measured With the Photonumeric Scale. — 21.25; 21.36; 21.21; 21.03 Units on a scale

Primary: The Efficacy of Restylane Vital on Skin Structure Compared to no Treatment Using a Validated Scale. — 0.85; 2.17 units on a scale

Primary: Analysis of Elasticity (Collagen & Elastin) — 1.7; 0.5; 1.5; 0.5 units on a scale

Primary: Day 180 Number of Participants With Improvement Measured By Independent Photographic Review — 6; 52 Participants — p=<0.0001

Primary: Hydration Level — 53.19; 46.75 AU (arbitrary unit) — p=<0.05

Primary: NIH Examiner Battery, Executive Composite Changes From Baseline to Post-testing — 0.33; 0.22 z-score — p=.575

Primary: Day 180 Number of Participants With Improvement in Lower Eyelid Area as Determined by a Masked, Qualitative Assessment. — 5 Participants

Primary: Mean Change From Baseline to 24 Weeks in Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) Using the Average of Scores at 12, 18 and 24 Weeks. — -9.76…

Primary: Degree of Improvement as Assessed by the Investigator (Physician's Global Assessment of Improvement). — 1.7 score on a scale

Primary: Full Face Global Aesthetic Improvement — 2.5 units on a scale

Primary: Change in the Wrinkle Severity Rating Scale (WSRS) With Subjects From Both the Retreatment and the Optimal Correction Groups - WSRS Scores at Visit 8/Week 52 — 0.1; 0.6…

Primary: FACE-Q Satisfaction With Facial Appearance Overall Scale — 42.35; 59.42 score on a scale

Primary: Degree of Improvement Rating at 12 Weeks Post-final Treatment — 1.4 score on a scale

Primary: Physician's Global Assessment of Improvement — 2 score on a scale

Primary: Change in Epigenetic Markers — 84.4; 82.8 years

Primary: Change From Baseline in Ra (a dermaTOP Parameter), of Test Product Treated Versus (vs.) Untreated Side at Day 29 — -1.90; -0.12 Micro meter (µm) — p=0.0638

Primary: First Impressions — 46.756; 27.769; 46.391; 34.404 score on a scale

Primary: The Number of Days Survived Without a Fall Over the 1 Year Duration of the Study — 239; 249.67 Days survived without a fall.

Primary: Effect of RF on Pelvic Floor Measured by Intentional Muscle Contraction Using Biofeedback EMS — 13.13 mV